Arcutis Biotherapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Arcutis Biotherapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q3 2024.
  • Arcutis Biotherapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 159 %, a 21.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 159 -43.5 -21.5% Sep 30, 2024
Q2 2024 185 +48.2 +35.2% Jun 30, 2024
Q1 2024 225 +124 +123% Mar 31, 2024
Q4 2023 275 +201 +269% Dec 31, 2023
Q3 2023 203 +147 +266% Sep 30, 2023
Q2 2023 137 +105 +334% Jun 30, 2023
Q1 2023 101 +81.1 +409% Mar 31, 2023
Q4 2022 74.6 +63.2 +557% Dec 31, 2022
Q3 2022 55.4 +49.4 +818% Sep 30, 2022
Q2 2022 31.5 +24.6 +352% Jun 30, 2022
Q1 2022 19.8 +11.1 +128% Mar 31, 2022
Q4 2021 11.4 +1.5 +15.2% Dec 31, 2021
Q3 2021 6.04 -5.78 -48.9% Sep 30, 2021
Q2 2021 6.98 Jun 30, 2021
Q1 2021 8.7 Mar 31, 2021
Q4 2020 9.85 Dec 31, 2020
Q3 2020 11.8 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.